<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083585</url>
  </required_header>
  <id_info>
    <org_study_id>CR109065</org_study_id>
    <secondary_id>VAC18193RSV3004</secondary_id>
    <nct_id>NCT05083585</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 65 Years Old</brief_title>
  <official_title>A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to Less Than 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority in terms of humoral immune&#xD;
      responses induced by vaccination with one dose of the Phase 3 clinical trial material (CTM)&#xD;
      compared with one dose of the Phase 2b CTM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">May 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prefusion Conformation-stabilized F Protein (pre-F) Enzyme-linked Immunosorbent Assay (ELISA) Antibody Titers</measure>
    <time_frame>14 days after vaccination (Day 15)</time_frame>
    <description>pre-F ELISA antibody titers at 14 days after vaccination will be reported. To demonstrate non-inferiority in terms of humoral immune responses induced by vaccination with one dose of the Phase 3 clinical trial material (CTM) compared with one dose of the Phase 2b CTM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Solicited Local Adverse Events (AEs) (Injection Site) for 7 Days after Vaccination</measure>
    <time_frame>Up to 7 days after vaccination (Up to Day 8)</time_frame>
    <description>Number of participants with solicited local AEs (injection site) for 7 days after vaccination will be reported. Solicited local AEs include injection site pain/tenderness, erythema and swelling (mild to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Solicited Systemic AEs for 7 Days after Vaccination</measure>
    <time_frame>Up to 7 days after vaccination (Up to Day 8)</time_frame>
    <description>Number of participants with solicited systemic AEs for 7 days after vaccination will be reported. Solicited systemic AEs include fatigue, headache, nausea, myalgia, and fever (mild to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Unsolicited AEs for 28 Days after Vaccination</measure>
    <time_frame>Up to 28 days after vaccination (Up to Day 29)</time_frame>
    <description>Number of participants with unsolicited AEs for 28 days after vaccination will be reported. Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs) until 6 Months after Vaccination</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants with SAEs until 6 months after vaccination will be reported. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events of Special Interest (AESIs) until 6 Months after Vaccination</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants with AESIs until 6 months after vaccination will be reported. Thrombosis with thrombocytopenia syndrome (TTS) is considered to be an AESI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Syncytial Virus (RSV) Neutralization Antibody (VNA_A2) Titers</measure>
    <time_frame>14 days post vaccination (Day 15)</time_frame>
    <description>RSV VNA titers at 14 days post vaccination will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Respiratory Syncytial Virus Prevention</condition>
  <arm_group>
    <arm_group_label>Group 1: Phase 3 Clinical Trial Material (CTM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intramuscular (IM) injection of adenovirus serotype 26 (Ad26). respiratory syncytial virus (RSV). prefusion conformation-stabilized F protein (preF)-based vaccine on Day 1, which is a Phase 3 CTM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Phase 2b CTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IM injection of Ad26.RSV.preF-based vaccine on Day 1, which is a Phase 2b CTM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF-based vaccine</intervention_name>
    <description>Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.</description>
    <arm_group_label>Group 1: Phase 3 Clinical Trial Material (CTM)</arm_group_label>
    <arm_group_label>Group 2: Phase 2b CTM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to adhere to the prohibitions and restrictions specified in the&#xD;
             protocol&#xD;
&#xD;
          -  Before randomization, a participant must be postmenopausal (postmenopausal state is&#xD;
             defined as no menses for 12 months without an alternative medical cause); and not&#xD;
             intending to conceive by any methods&#xD;
&#xD;
          -  In the investigator's clinical judgment, participant must be in stable health at the&#xD;
             time of vaccination. Participants may have underlying illnesses such as hypertension,&#xD;
             congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes,&#xD;
             hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are&#xD;
             stable at the time of vaccination, and these conditions receive routine follow-up by&#xD;
             the participant's healthcare provider. Participants will be included on the basis of&#xD;
             medical history, and vital signs performed between informed consent form (ICF)&#xD;
             signature and vaccination&#xD;
&#xD;
          -  Must be willing to provide verifiable identification, has means to be contacted and to&#xD;
             contact the investigator during the study&#xD;
&#xD;
          -  From the time of vaccination through 3 months after vaccination, agrees not to donate&#xD;
             blood&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy or history of anaphylaxis or other serious adverse&#xD;
             reactions to vaccines or their excipients (including specifically the excipients of&#xD;
             the study vaccine)&#xD;
&#xD;
          -  Abnormal function of the immune system resulting from clinical condition or medication&#xD;
&#xD;
          -  History of acute polyneuropathy (example, Guillain-Barr√© syndrome) or chronic&#xD;
             idiopathic demyelinating polyneuropathy&#xD;
&#xD;
          -  History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced&#xD;
             thrombocytopenia and thrombosis (HITT)&#xD;
&#xD;
          -  Has had major surgery (per the investigator's judgment) within 4 weeks before&#xD;
             administration of the study vaccine or will not have recovered from surgery per the&#xD;
             investigator's judgment at time of vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109065</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

